PE20091624A1 - Farmaco combinado a base de un inhibidor de her2 derivado de pirrolopirimidina o pirazolopirimidina - Google Patents

Farmaco combinado a base de un inhibidor de her2 derivado de pirrolopirimidina o pirazolopirimidina

Info

Publication number
PE20091624A1
PE20091624A1 PE2009000317A PE2009000317A PE20091624A1 PE 20091624 A1 PE20091624 A1 PE 20091624A1 PE 2009000317 A PE2009000317 A PE 2009000317A PE 2009000317 A PE2009000317 A PE 2009000317A PE 20091624 A1 PE20091624 A1 PE 20091624A1
Authority
PE
Peru
Prior art keywords
inhibitor
pyrrolopyrimidine
pyrazolopyrimidine
her2 inhibitor
cancer
Prior art date
Application number
PE2009000317A
Other languages
English (en)
Inventor
Yoshikazu Ohta
Shinji Takagi
Masahiro Yaguchi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20091624A1 publication Critical patent/PE20091624A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN INHIBIDOR DE HER2 DERIVADO PIRROLOPIRIMIDINA O PIRAZOLOPIRIMIDINA DE FORMULA (I) Y B) UN AGENTE SELECCIONADO DE UN INHIBIDOR DE mTOR TAL COMO RAPAMICINA, UN INHIBIDOR DE PI3 QUINASA TAL COMO PI-103 Y UN INHIBIDOR DE Cmet TAL COMO PF2341066, DONDE W ES C(R1) O N; R1 ES H; A ES ARILO C6-C18 O HETEROARILO; X1 ES -O-, -S-, -SO-, ENTRE OTROS; R2 ES H O UN GRUPO OPCIONALMENTE SUSTITUIDO UNIDO A TRAVES DE UN ATOMO DE CARBONO, UN ATOMO DE NITROGENO O UN ATOMO DE OXIGENO. EL INHIBIDOR DE HER2 ES N-{2-[4-({3-CLORO-4-[3-(TRIFLUOROMETIL)FENOXI]FENIL}AMINO)-5H-PIRROLO[3,2-d]PIRIMIDIN-5-IL]ETIL}-3-HIDROXI-3-METILBUTANAMIDA. DICHA COMPOSICION ES UNA COMBINACION SINERGICA UTIL EN EL TRATAMIENTO DEL CANCER TALES COMO CANCER DE MAMA, CANCER DE PROSTATA, CANCER DE PULMON, ENTRE OTROS
PE2009000317A 2008-03-03 2009-03-02 Farmaco combinado a base de un inhibidor de her2 derivado de pirrolopirimidina o pirazolopirimidina PE20091624A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008052615 2008-03-03

Publications (1)

Publication Number Publication Date
PE20091624A1 true PE20091624A1 (es) 2009-11-19

Family

ID=41055970

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000317A PE20091624A1 (es) 2008-03-03 2009-03-02 Farmaco combinado a base de un inhibidor de her2 derivado de pirrolopirimidina o pirazolopirimidina

Country Status (8)

Country Link
US (1) US20110003805A1 (es)
EP (1) EP2255830A1 (es)
JP (1) JPWO2009110415A1 (es)
AR (1) AR071645A1 (es)
PE (1) PE20091624A1 (es)
TW (1) TW200942544A (es)
UY (1) UY31684A (es)
WO (1) WO2009110415A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102558185B (zh) * 2010-12-09 2016-02-10 中国科学院上海药物研究所 吡啶并吡咯三嗪化合物、其制备方法和用途
US9145390B2 (en) 2011-03-03 2015-09-29 Concert Pharmaceuticals, Inc. Derivatives of pyrazole-substituted amino-heteroaryl compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
EP1615906A1 (en) 2003-04-03 2006-01-18 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
JP4366683B2 (ja) 2003-07-28 2009-11-18 武原 力 熱サイホン
EP1648452B1 (en) 2003-07-28 2009-07-22 Merck Serono SA 2-imino-4-(thio)oxo-5-polycyclovinylazolines for use as pi3 kinase inhibitors
MEP8409A (en) * 2004-06-02 2011-12-20 Fused heterocyclic compound
KR20070034536A (ko) 2004-06-04 2007-03-28 스미스클라인 비이참 (코르크) 리미티드 암 치료 방법
CN101522687A (zh) 2006-01-30 2009-09-02 阿雷生物药品公司 用于癌症治疗的杂二环噻吩化合物
TWI398252B (zh) * 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途

Also Published As

Publication number Publication date
US20110003805A1 (en) 2011-01-06
WO2009110415A1 (ja) 2009-09-11
EP2255830A1 (en) 2010-12-01
TW200942544A (en) 2009-10-16
UY31684A (es) 2009-11-10
AR071645A1 (es) 2010-07-07
JPWO2009110415A1 (ja) 2011-07-14

Similar Documents

Publication Publication Date Title
PE20140378A1 (es) Compuestos y composiciones como inhibidores de la trk
UA108640C2 (uk) Похідні n-(імідазопіримідин-7-іл)гетероариламідів та їх застосування як інгібіторів pde10a
PE20120575A1 (es) Derivados de pirazolopirimidina como inhibidores de jak quinasas
EA201100136A1 (ru) 2,4'-бипиридинилы в качестве ингибиторов протеинкиназы d, применимые для лечения сердечной недостаточности и рака
MX356176B (es) Metodos para usar moduladores de c-met.
EA201390085A1 (ru) Композиции ингибиторов киназ для лечения рака
MX2012013907A (es) Compuestos heteroarilo nitrogenados.
HK1139863A1 (en) Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
CY1117067T1 (el) Η χρηση σωματιδιων στερεων φορεων για τη βελτιωση της επεξεργασιμοτητας φαρμακευτικου παραγοντα
MX2013010770A (es) Tratamiento de tumores solidos.
GEP201706703B (en) Boronate ester compounds and pharmaceutical compositions thereof
NZ621433A (en) Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
CL2009000687A1 (es) Compuestos derivados de heterociclos nitrogenados de imidazol, inhibidores de la actividad de cinasa raf; composicion farmaceutica; utiles para el tratamiento del cancer, tal como carcinoma de pulmon, pancreatico, de prostata, tiroides, entre otras.
MX2012007536A (es) Derivados de heteroarilo que contienen nitrogeno.
UA96076C2 (en) Use of trans-clomiphene
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
NO20071428L (no) Kombinasjon inneholdende ZD6474 og Imatinib
EP2337561A4 (en) USE OF A TOCOTRIENOL COMPOSITION FOR THE PREVENTION OF CANCER
RU2013141559A (ru) Способ ингибирования клеток опухоли гамартомы
RU2015102772A (ru) Бензодиазелипы для мелкоклеточного рака легкого
MX2011011083A (es) Compuestos heterociclicos como inhibidores de mek.
NZ611581A (en) Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer
GEP201706656B (en) 2-thiopyrimidinones
NZ606730A (en) Methods for treating antipsychotic-induced weight gain
MX345467B (es) Metodo para inhibicion de actividad desubiquitinante.

Legal Events

Date Code Title Description
FD Application declared void or lapsed